No connection

Search Results

SPRO vs TKNO

SPRO
Spero Therapeutics, Inc.
BEARISH
Price
$2.75
Market Cap
$159.2M
Sector
Healthcare
AI Confidence
85%
TKNO
Alpha Teknova, Inc.
BEARISH
Price
$2.91
Market Cap
$155.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
SPRO
18.33
TKNO
--
Forward P/E
SPRO
-2.48
TKNO
-7.46
P/B Ratio
SPRO
2.63
TKNO
2.27
P/S Ratio
SPRO
2.38
TKNO
3.85
EV/EBITDA
SPRO
17.01
TKNO
-16.07

Profitability

Gross Margin
SPRO
42.42%
TKNO
33.17%
Operating Margin
SPRO
76.05%
TKNO
-41.16%
Profit Margin
SPRO
12.83%
TKNO
-42.59%
ROE
SPRO
16.3%
TKNO
-22.83%
ROA
SPRO
4.99%
TKNO
-9.26%

Growth

Revenue Growth
SPRO
174.5%
TKNO
7.8%
Earnings Growth
SPRO
--
TKNO
--

Financial Health

Debt/Equity
SPRO
0.05
TKNO
0.41
Current Ratio
SPRO
7.59
TKNO
4.58
Quick Ratio
SPRO
7.4
TKNO
3.44

Dividends

Dividend Yield
SPRO
--
TKNO
--
Payout Ratio
SPRO
0.0%
TKNO
0.0%

AI Verdict

SPRO BEARISH

SPRO exhibits a critical divergence between its explosive revenue growth and its underlying financial health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a strong current ratio (7.59) and low debt, the current price of $2.75 trades at a significant premium to both its Graham Number ($1.88) and Intrinsic Value ($1.05). This valuation gap, combined with aggressive insider selling by the CEO and COO and a bearish technical trend, suggests the recent 1-year price surge is unsustainable. The negative forward P/E further indicates an expectation of returning to losses despite recent revenue spikes.

Strengths
Exceptional YoY revenue growth of 174.50%
Very high liquidity with a current ratio of 7.59
Minimal leverage with a Debt/Equity ratio of 0.05
Risks
Severe financial health deterioration indicated by Piotroski F-Score (2/9)
Strong bearish insider signal with multiple sales by CEO and COO
Significant overvaluation relative to Graham and Intrinsic value baselines
TKNO BEARISH

TKNO exhibits severe financial weakness with a Piotroski F-Score of 1/9, indicating critical operational deterioration. While the company maintains a strong liquidity buffer with a current ratio of 4.58 and low debt-to-equity (0.41), it is plagued by deep negative profit margins (-42.59%) and a completely bearish technical trend (0/100). There is a significant disconnect between the optimistic analyst target of $9.00 and the market's reality, evidenced by a 49.6% price decline over the last year. The lack of profitability and poor deterministic health scores make this a high-risk speculative play.

Strengths
Strong short-term liquidity (Current Ratio: 4.58)
Low leverage (Debt/Equity: 0.41)
Positive YoY EPS growth (+18.2%) despite remaining negative
Risks
Critical operational health (Piotroski F-Score: 1/9)
Severe negative profitability (Profit Margin: -42.59%)
Strong bearish technical momentum (Technical Trend: 0/100)

Compare Another Pair

SPRO vs TKNO: Head-to-Head Comparison

This page compares Spero Therapeutics, Inc. (SPRO) and Alpha Teknova, Inc. (TKNO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile